DK0882132T3 - Et kombineret humant cytomegalovirus-antigen og anvendelse heraf - Google Patents
Et kombineret humant cytomegalovirus-antigen og anvendelse herafInfo
- Publication number
- DK0882132T3 DK0882132T3 DK97905078T DK97905078T DK0882132T3 DK 0882132 T3 DK0882132 T3 DK 0882132T3 DK 97905078 T DK97905078 T DK 97905078T DK 97905078 T DK97905078 T DK 97905078T DK 0882132 T3 DK0882132 T3 DK 0882132T3
- Authority
- DK
- Denmark
- Prior art keywords
- human cytomegalovirus
- hcmv
- combined human
- cytomegalovirus antigen
- specific antibodies
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title abstract 6
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/605,541 US5800981A (en) | 1996-02-22 | 1996-02-22 | Human cytomegalovirus antigen and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0882132T3 true DK0882132T3 (da) | 2006-03-06 |
Family
ID=24424094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97905078T DK0882132T3 (da) | 1996-02-22 | 1997-02-20 | Et kombineret humant cytomegalovirus-antigen og anvendelse heraf |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5800981A (da) |
| EP (1) | EP0882132B1 (da) |
| JP (1) | JP2001517072A (da) |
| AT (1) | ATE307207T1 (da) |
| AU (1) | AU732254B2 (da) |
| DE (1) | DE69734387T2 (da) |
| DK (1) | DK0882132T3 (da) |
| ES (1) | ES2251016T3 (da) |
| WO (1) | WO1997031117A2 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2757169B1 (fr) * | 1996-12-13 | 1999-03-05 | Inst Nat Sante Rech Med | Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin |
| DE19910044A1 (de) * | 1999-03-08 | 2000-09-14 | Bodo Plachter | Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff |
| EP1057895A1 (de) * | 1999-06-04 | 2000-12-06 | Lohmann Animal Health GmbH & Co. KG | Fusionsprotein das das Fragment B des Shigatoxins enthält, dieses enthaltende (Impf-)Stoffzusammensetzung und Verfahren zu dessen Herstellung |
| US6569616B1 (en) * | 1999-07-29 | 2003-05-27 | Wisconsin Alumni Research Foundation | Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate |
| ES2429338T3 (es) * | 2002-12-23 | 2013-11-14 | Vical Incorporated | Vacuna basada en polinucleótidos optimizados por codones contra infección por citomegalovirus humano |
| US20040228842A1 (en) * | 2003-02-27 | 2004-11-18 | Shan Lu | Compositions and methods for cytomegalovirus treatment |
| AU2005336856A1 (en) * | 2005-09-27 | 2007-04-05 | Oncalis Ag | Genetic selection system to identify proteases, protease substrates and protease inhibitors |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| US7947274B2 (en) | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
| CN106924729B (zh) | 2008-07-16 | 2021-03-02 | 生物医学研究学会 | 人巨细胞病毒中和抗体及其应用 |
| SG181901A1 (en) | 2009-12-23 | 2012-08-30 | 4Antibody Ag | Binding members for human cytomegalovirus |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1266740B1 (it) * | 1994-07-01 | 1997-01-14 | Maria Paola Landini | Materiale proteico ricombinante legante anticorpi contro il citomegalovirus umano, reagenti diagnostici derivati da tale |
| DE4426453C1 (de) * | 1994-07-26 | 1995-11-02 | Biotest Ag | Rekombinant hergestellte Fusionsproteine des Cytomegalievirus und diese enthaltende diagnostische Testkits |
-
1996
- 1996-02-22 US US08/605,541 patent/US5800981A/en not_active Expired - Lifetime
-
1997
- 1997-02-20 AU AU18763/97A patent/AU732254B2/en not_active Ceased
- 1997-02-20 DE DE69734387T patent/DE69734387T2/de not_active Expired - Lifetime
- 1997-02-20 AT AT97905078T patent/ATE307207T1/de not_active IP Right Cessation
- 1997-02-20 ES ES97905078T patent/ES2251016T3/es not_active Expired - Lifetime
- 1997-02-20 EP EP97905078A patent/EP0882132B1/en not_active Expired - Lifetime
- 1997-02-20 JP JP52981597A patent/JP2001517072A/ja active Pending
- 1997-02-20 DK DK97905078T patent/DK0882132T3/da active
- 1997-02-20 WO PCT/EP1997/000865 patent/WO1997031117A2/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997031117A3 (en) | 1997-10-02 |
| WO1997031117A2 (en) | 1997-08-28 |
| DE69734387D1 (de) | 2006-03-02 |
| JP2001517072A (ja) | 2001-10-02 |
| DE69734387T2 (de) | 2006-07-06 |
| ATE307207T1 (de) | 2005-11-15 |
| AU1876397A (en) | 1997-09-10 |
| EP0882132A2 (en) | 1998-12-09 |
| US5800981A (en) | 1998-09-01 |
| AU732254B2 (en) | 2001-04-12 |
| EP0882132B1 (en) | 2005-10-19 |
| ES2251016T3 (es) | 2006-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0882132T3 (da) | Et kombineret humant cytomegalovirus-antigen og anvendelse heraf | |
| WO2003048337A3 (en) | Antibody to latent membrane proteins and uses thereof | |
| EP0344940A3 (en) | Antibodies to human papillomavirus latent proteins, diagnostic systems and methods | |
| NO970221D0 (no) | Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus | |
| NO991449L (no) | Antistoff mot human parathormon-relaterte peptider | |
| ATE312920T1 (de) | Dna immunisierung gegen chlamydia infektion | |
| AU1866895A (en) | Human monoclonal antibodies to herpes simplex virus and methods therefor | |
| FI910497A0 (fi) | Nytt virus vid infektioes bursalsjukdom. | |
| GB8404368D0 (en) | Monoclonal antibodies to human cytomegalovirus | |
| DE69629674D1 (de) | Dns-sequenzen des humanen cytomegaloviruses | |
| ATE171473T1 (de) | Humanisierte monoklonale antikörper gegen humanes interleukin - 4 | |
| WO1995016040A3 (en) | Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form | |
| DK364286D0 (da) | Varicella-zoster virus (vzv) ga, gb og gc glycoproteiner i renset, ikke-denatureret, serologisk aktiv form og fremgangsmaade til proevning for tilstedevaerelsen af antistoffer over for disse | |
| AU3245000A (en) | Compounds and methods for the detection and prevention of (t. cruzi) infection | |
| AU2133292A (en) | Hcmv-specific peptides, agents therefor and the use thereof | |
| CA2246802A1 (en) | A human cytomegalovirus combined antigen and its use | |
| DE69028561T2 (de) | Immunoassay zum Nachweis von Antikörpern gegen HIV | |
| KR950702244A (ko) | 백신으로서의 즉석 초기 hsv-2 비루스 단백질 icp27(immediatie early hsv-2 viral protein icp27 as vaccine) | |
| FR2737209B1 (fr) | Peptide capable d'etre reconnu par des anticorps reconnaissant l'antigene c33 du virus de l'hepatite c | |
| AP9300556A0 (en) | Peptides,analogues and mixtures thereof for detecting and eliciting antibodies to the e1 and e2 protein of rubella virus | |
| ES2013665A6 (es) | Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso. | |
| AU3481389A (en) | Antibodies to human papillomavirus latent proteins, diagnostic systems and methods | |
| FI950253A0 (fi) | Fimbria-antigeenejä, -vasta-aineita, -osoitusmenetFimbria-antigeenejä, -vasta-aineita, -osoitusmenetelmiä ja -rokotteita elmiä ja -rokotteita | |
| Narayan | Int J Zoonoses. 1983 Dec; 10 (2): 105-10. Related Articles, Links Use of enzyme linked immunosorbent assay (ELISA) in the quantitation of Clostridium perfringens type A enterotoxin and antienterotoxin antibodies. Narayan KG, Genigeorgis C, Behymer D. ELISA procedure for quantitation of enterotoxin of Clostridium perfringens type A was | |
| AU2370692A (en) | Method to detect antibodies against hepatitis c virus and kits for the use thereof |